

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

BIOTRANSPLANT INC  
Form 8-K  
February 21, 2001

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2001

BIOTRANSPLANT INCORPORATED

(Exact name of registrant as specified in its charter)

|   |                          |                                      |
|---|--------------------------|--------------------------------------|
| DELAWARE  | 000-28324                | 04-3119555                           |
| -----   | -----                    | -----                                |
| (State or other jurisdiction of<br>incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

|   |            |
|---|------------|
| Building 75, Third Avenue<br>Charlestown Navy Yard<br>Charlestown, MA | 02129      |
| -----   | -----      |
| (Address of principal executive<br>offices)                           | (Zip Code) |

Registrant's telephone number, including area code: (617) 241-5200

N/A

-----  
(Former name or former address, if changed since last report)

Item 5. Other Events.

On February 21, 2001, BioTransplant Incorporated issued a press release announcing that Eligix, Inc. had received European Community authorization to affix the CE Mark to its B-Cell HDM cell separation devices. See the press release attached hereto as Exhibit 99.1.

## Edgar Filing: BIOTRANSPLANT INC - Form 8-K

On February 21, 2001, Dr. Elliot Lebowitz, President and Chief Executive Officer of BioTransplant Incorporated, made a slide presentation at the BIO-CEO Conference relating to BioTransplant's business and its proposed merger with Eligix, Inc. See the text of the slide presentation attached hereto as Exhibit 99.2.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

See Exhibit Index attached hereto.

2

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 21, 2001

BIOTRANSPLANT INCORPORATED

By: /s/ Richard V. Capasso

-----  
Richard V. Capasso  
Vice President, Finance and Treasurer

3

### EXHIBIT INDEX

| EXHIBIT NO.  | EXHIBIT   |
|--------------|---|
| Exhibit 99.1 | Press Release dated February 21, 2001                     |
| Exhibit 99.2 | Text of the slide presentation given on February 21, 2001 |

4